AC Immune FY2024 EPS Forecast Boosted by Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for AC Immune in a report released on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($0.60) per share for the year, up from their previous estimate of ($0.81). The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.87) EPS and FY2028 earnings at $0.00 EPS.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.67). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $91.60 million.

A number of other equities analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a report on Wednesday. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Performance

NASDAQ ACIU opened at $3.27 on Friday. The company has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $3.45. AC Immune has a 52 week low of $2.25 and a 52 week high of $5.14.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC bought a new stake in AC Immune during the second quarter worth approximately $40,000. Lazard Asset Management LLC bought a new stake in shares of AC Immune in the 1st quarter worth $30,000. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after buying an additional 8,423 shares in the last quarter. Vanguard Capital Wealth Advisors acquired a new stake in shares of AC Immune in the second quarter valued at $56,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.